20h
MedPage Today on MSNStudies Hint at Potential Negative Effects of GLP-1 Drugs in Orthopedic PatientsSAN DIEGO -- Two retrospective studies hinted at potential negative effects of GLP-1 receptor agonists for patients requiring ...
G lucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have ...
Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight ...
NotCo announced Thursday the launch of its GLP Booster, a product that can be mixed into any food to naturally help you feel ...
For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...
As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...
GLP-1 therapy is a groundbreaking approach in the treatment of obesity and metabolic health issues. GLP-1, or glucagon-like ...
Opinion
9hOpinion
The Journal News on MSNGLP-1 drugs should require eating disorder screening before prescription | OpinionBy screening people for eating disorders and disordered eating before these medications are prescribed, we can prevent unintended consequences.
A recent study suggests that GLP-1 receptor agonists (GLP-1RAs) may lower the risk of hematologic cancers, including leukemia ...
The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...
Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management.
Vivani Medical (Nasdaq:VANI) announced today that it successfully administered the first GLP-1 implant in its LIBERATE-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results